Abstract
The mammalian cerebral cortex is critical for sensory and motor integrations and, for higher-order cognitive functions. The construction of mammalian cortical circuits involves the coordinated interplay between cellular processes such as proliferation, migration and differentiation of neural and glial cell subtypes followed by accurate connectivity evolving in complexity in primates. Alteration in cortical development may induce the emergence of various pathological traits and behaviours. Among the large array of factors that regulate the assembly of cortical circuits, serotonin (5-HT) plays important role as a developmental signal that impacts on a broad diversity of cellular processes. 5-HT plays distinct roles during specific sensitive periods and is produced from various sources depending on the perinatal stage. Its roles are mediated by more than fourteen 5-HT receptors that are all G-protein coupled receptors except the ionotropic 5-HT type 3A receptor (5-HT3A) mediating rapid neuronal activation. Importantly, 5-HT metabolism and signalling are influenced by numerous epigenetic and genetic factors, including nutrition and gut microbiota, perinatal stress, infection and inflammation. In this review, we will recapitulate some evidences showing that dysregulation of 5-HT homeostasis and 5-HT3A signalling impairs distinct steps of cortical circuit formation leading to the predisposition of the onset of various psychiatric diseases.
Keywords
- development
- human
- monoamine
- plasticity
- 5-HT3 receptor
1. Introduction
The functions of the mammalian cerebral cortex are processed through the activation of multipartite neural networks composed of excitatory glutamatergic pyramidal neurons, local modulatory interneurons that release γ-aminobutyric acid (GABA), neuropeptides and vasoactive substances [1–5] and by ‘glial cells’ that do far more than just feeding neurones and scavenging debris [6, 7]. Developmental perturbations impacting the maturation of cortical circuits can trigger neuropsychiatric disorders [8–10]. Sensitive periods or windows of vulnerability have been demonstrated in various processes in particular for the rodent sensory systems as well as in the modulation of complex behaviours.
Mammalian cortical circuit formation is the result of a series of sequential events that take place mainly during embryonic and early post-natal development [11–14]. These events include the proliferation, migration and differentiation of neurons and ‘glial cells’ that are largely governed by genetic programs but are also sensitive to environmental factors. Such extrinsic signals are extremely diverse (including guidance cues, growth factors, cell adhesion molecules) and among them the monoamine serotonin (5-HT) has emerged as an important regulator of neural circuit formation [15, 16].
In mammals, cortical 5-HT arises from multiples sources depending on the developmental stage. At the onset of cortical development, 5-HT is of maternal and placental origin [17–19]. Later, by embryonic day 16 (E16 in mice) [15, 16, 20] and by gestational week 16 (GW16 in human) [13, 14], serotoninergic afferents invade the cerebral cortex and contribute to provide 5-HT locally. Not surprisingly, like in non-mammalian species, serotonin modulates neuronal proliferation, migration and differentiation. In addition, 5-HT is implicated in the emergence of many neuropsychiatric disorders, including mental retardation, autism, depression and anxiety [10, 15, 21–26]. Importantly, 5-HT signalling is influenced by numerous epigenetic and genetic factors, including nutrition and gut microbiota [27, 28], perinatal stress [29–31], infection and inflammation [32–35], 5-HT metabolism and storage [15, 36–38], pharmacological compounds such as selective serotonin reuptake inhibitors [38–40] and genetic alterations [41–44].
Our aim is to give a comprehensive overview on the possible roles of 5-HT receptor signalling and 5-HT homeostasis on the development of the cerebral cortex in rodent and primate with a specific emphasis on human. In this framework, we will highlight more particularly recent studies that have revealed new molecular targets of early-life 5-HT in the construction of cortical circuits; in particular, the ionotropic 5-HT type 3A receptor (5-HT3A). We will also review recent clinical studies suggesting that altered 5-HT homeostasis or signalling could participate in the emergence of human psychiatric disease, in particular of mood and anxiety disorders.
2. Structure and development of the mammalian cerebral cortex
2.1. Neuronal components and glial components
The mammalian cerebral cortex comprises of six lamina (layers), each containing specific combination of neurons and ‘glial cells’. Cortical excitability is coordinated by the interplay of excitatory pyramidal neurons and inhibitory interneurons. Pyramidal cells, which make up the majority of all neurons in the adult cortex (80% in rodent cortex), are projection neurons that send axons to other areas inside or outside the cortex providing output excitatory drive by releasing glutamate [2]. Inhibitory neurons project locally, release the neurotransmitter GABA and refine cortical excitability. Although GABAergic interneurons are less abundant, they have crucial roles in the development and organization of cortical networks that underlie a wide range of cortical and mental functions [8, 45, 46]. They are extremely diverse, differing in shape, electrophysiological properties and in the combination of neuropeptides and calcium-binding proteins that they express in addition to GABA [1, 47]. To facilitate the description of GABAergic neurons, a consortium of experts has suggested using a unified nomenclature [4, 5]. Thus, one can distinguish four major and highly distinct classes of GABAergic neurons in the mammalian cerebral cortex (Figure 1A). First, fast-spiking interneurons expressing parvalbumin (PV) that gate incoming sensory information [48, 49]. Second, adapting Martinotti cells expressing somatostatin (SOM) that control dendritic information through local feedback inhibition [50]. Third, adapting bipolar interneurons expressing mainly the vasoactive intestinal peptide (VIP) and calretinin (CR) that preferentially target other interneurons and receive direct input from the thalamus [20, 51, 52]. Fourth, adapting neurogliaform interneurons expressing vasoactive substances, notably the neuropeptide Y (NPY) and/or nitric oxide (NO) that are responsible for the slow GABAergic inhibition of pyramidal cells and interneurons and vasomotion [53–56].

Figure 1.
Structure of the rodent cerebral cortex and relation with serotoninergic afferents. A, The four main classes of interneurons (NG: neurogliaform, PV: parvalbumin+, VIP: vasoactive intestine peptide+, SOM: somatostatin+) and their relationship with a typical pyramidal glutamatergic neuron (adapted from [
Although these different types of interneurons have been identified in the primate or human cerebral cortex, their diversity largely surpasses what is observed in rodent [12]. Interestingly, unique to human cerebral cortex, bipolar/von Economo neurons are present in layer V of the anterior cingulate and fronto-insular cortices expressing VMAT2 [57, 58]. Their possible involvement suggested in neuropsychiatric disorders needs to be further investigated [59]. In human and primate, the neuronal composition of the cerebral cortex is less homogeneous between areas with a higher level of arealisation than in rodent. Interestingly, the density of small interneurons appears very high in associative areas [60].
Besides neurons, mature ‘glial cells’ have been shown to exert roles that are extremely more complex than previously thought. Astrocytes are the largest glial population in the mammalian brain and are well-known to ‘feed neurons’ by transforming glucose into lactate that neurons can directly use as ‘carburant’, to scavenge debris and to regulate neural transmission and ionic homeostasis of the brain [61, 62]. Microglial cells play a role of sentinels of inflammatory state of the brain. In addition to these roles, astrocytes and microglial cells participate in regulating cell proliferation, neuronal migration and plasticity (for review, see Refs. [6, 61, 63]). Oligodendrocytes myelinate axons and increase their conduction velocity (they will not be further described in this chapter).
2.2. Development of the rodent cerebral cortex
The cerebral cortex develops from neuroepithelial germinal cells of the telencephalic pallium and subpallium that massively proliferate by E11-E12 in mice and GW5-6 in human, to form the cerebral vesicles [66]. At this stage, microglial cells—of extracerebral origin—have already started to invade the telencephalon (from E9.5 in rodent [67] and GW5 in human [63]) before blood vessels start to penetrate and ramify in the telencephalon [68]. They will both participate in regulating neurogenesis [69]. The first generated neurons, Cajal-Retzius (C-R) cells and subplate cells (SP; from E10 in mice, GW5-7 in human), constitute transient and heterogeneous populations of cells that originate from both pallial and subpallial territories and form the preplate (PP; Boulder Committee; [66, 70, 71]). SP and reelin-secreting C-R cells provide positioning cues and instructions to developing cortical neurons and afferents [71–74]. The cortical plate, is formed from E13-E17 in mice and GW7-20 in human by post-mitotic excitatory pyramidal neurons migrated along radial glial (RG) fibres in an inside out gradient of development from layer VIa to layer II [13]. At the beginning of cortical plate formation (E13-E14 in mice), pyramidal cells are generated from radial glial cells (RGC), whereas later (E15-E17 in mice), they mainly originate from intermediate progenitor cells (IPC) or basal progenitors deriving from RGC cells [75, 76] (Figure 2).

Figure 2.
Early stages of development of the human (A) and mouse (B) cerebral cortex in relation with 5-HT afferents. A-B, Both in human and rodent intense proliferation of neuroepithelium and the formation of the preplate (PP) take place around (E10; GW5) and (E11-E12; GW6-7) respectively. By E13-E14 in mice and GW8-10 in human, PP is split by the migration of the first pyramidal neurons. Cajal-Retzius cells (C-R) will remain in the marginal zone (MZ) while subplate neurons (SP) will be positioned below the cortical plate (CP). In addition, in human around GW10, another source of progenitors arises: the outer radial glial (oRG) cells that do not maintain contacts with the apical surface. Monoaminergic axons and thalamocortical axons (TC) are already found in the MZ and in the intermediate zone (IZ) and, in the IZ respectively. By E15-E16 in mice most glutamatergic neurons are generated, 5-HT axons and TC run in the MZ and IZ and in the IZ respectively. By GW16 in human, SP occupy a large proportion of the cortical anlage and oRG are still producing a high amount of neurons. Interneurons migrating first tangentially to the pial surface and later radially to it, incorporating CP. C, Bars indicate the time at which different factors (maternal and environmental; 5-HT of placental origin, 5-HT produced by the embryo itself) could affect the development of the mouse embryo. A, is adapted from [
The primate/human cortical neurogenesis is far more complex than that of rodent involving more germinal zones and a larger number of cell types [77, 78]. In particular, beside the early RGC in the VZ, a novel class of radial cells, the outer RG (oRG), located in the outer subventricular zone (SVZ) could be responsible for the increasing number of excitatory neurons and the formation of gyration in primate. The second stage of human cortical development (GW18-20) corresponds to the genesis of the supragranular layers that likely expand from the oRG [14] (Figure 2A).
In rodent, the cortical GABAergic interneurons are generated outside the cortical VZ, in the subpallium: mainly in the medial ganglionic eminence (MGE) (E11-E14 in mice) and the caudal ganglionic eminence (CGE) (E14-E17 in mice) [11, 20, 52]. These regions are specified through a combination of distinct transcription factors and morphogenes that produce different classes of interneurons [80]. The ventral and the dorsal parts of the MGE expressing the homeobox transcription factor Lhx6 generate fast-spiking/PV+ and adapting/SOM+ interneurons [81–85]. The CGE, a region that expresses the transcription factor Gsh2, COUP-TFII but lacks the transcription factors Nkx2.1, Nkx6.2 and Lhx6 [80, 86, 87], generates VIP+, CR+, NPY+ and nNOS+ interneurons [20, 52, 85, 88]. Once produced, interneurons are targeted towards specific brain regions, including cortex, depending on the transcription factors and guidance cues they express [87, 89]. They initially follow parallel migratory streams, first in the IZ and MZ and later on along the SVZ, before they switch their migratory mode and incorporate into the developing CP through radial migration (see Figure 2B). In mice, cortical migration is almost completed by P4, and is followed by cortical expansion. However, during the first two post-natal weeks and decreasing with age the SVZ retains the capacity to produce CR+ interneurons contributing to the pools of GABAergic neurons mainly populating lower cortical layers and cingulate cortex [90–92]. These events are recapitulated in Figure 3A and B.

Figure 3.
Presumptive genesis of cortical GABAergic neurons in the rodent and human/primate embryos and fetuses. (A and B) In rodent, PV+ and SOM+ interneurons (INs) are generated first from the medial ganglionic eminence (MGE) located in the anterior telencephalon. CR+, VIP+ and neurogliaform INs are generated mainly in the caudal GE (CGE) and in the lateral GE (LGE) located in the basal ganglia and to a lesser extent in the anterior entopeduncular area (AEP) and in the pre-optic area (POA). (C) In non-human primate and in human, the picture is less clear. However transcription factors expression suggest that the GE produce a large part of GABAergic neurons. By contrast to rodent brain numerous, INs may be generated in the cortical anlage. Panel C is adapted from Ref. [
In non-human and human primate, the origin of the very heterogenous GABAergic interneurons is not so clear. Recently, studies have shown that in non-human primate, interneurons use a similar coding of transcription factors as in rodents and largely originate from the ganglionic eminences [93] (Figure 3C). However, a substantial proportion of them is likely to be generated in the pallium from the VZ and the SVZ [12, 94–96] (Figure 3C). Recently, migration of subclasses of human cortical interneurons has been reported to continue after birth [97].
2.3. Specificities of the human and primate cerebral cortex
As already mentioned, the first generated neurons, C-R and SP cells are located respectively in the presumptive Layer 1 and the SP zone of the human cortical anlage [66, 98, 99]. Specific to human, the SP zone is the largest transient compartment of the fetal neocortical anlage, about four times thicker than the cortical plate around midgestation [66, 100]. In humans and non-human primate, most SP neurons generated in the ventricular zone initially migrate radially, together with prospective layer VI neurons and secondarily get widespread into the expanding SP zone around midgestation [101]. Interestingly, at this stage, dispersion of SP cells in the extended SP zone is concomitant with the invasion of monoaminergic [102], thalamocortical and corticocortical axons in the cortical anlage [103]. SP zone begins slowly to disappear towards the end of gestation and during the early post-natal period. Finally, many subplate neurons survive postnatally and transform into interstitial neurons of the subcortical white matter of the adolescent and adult brain [104]. GABA+ interstitial neurons express CB and CR [105]. Subcortical interstitial neurons in the white matter, which have been associated with a variety of neurological and psychiatric disorders of infant and adults, need to be further investigated [105, 106]. Comparison of the rodent/human cortical development could be obtained by comparing Figure 2A with B and Figure 3A and B with C.
Microglial cells take part in normal establishment and maturation of neuronal circuitry during development [107]. In human, amoeboid microglial cells infiltrate the brain via the choroid plexus, the meninges and the ventricles around GW4,5, progressively colonize the cerebral wall from GW7 and became ramified [108, 109]. Passing through walls from GW10 on. Interestingly, amoeboid microglial cells cluster in a band at the limit of the CP/IZ-SP zone at GW9-13 where early synaptogenesis takes place in the cerebral anlage [110]. They also clustered in major axonal crossroads in the corpus callosum at GW16 and in the coronal radiata at GW19-24 [63]. Interestingly, this last fibres tract area is the target of white matter injury observed in inflammatory process of premature infant in cerebral palsy [111]. Similarly, a cluster of microglia/macrophages is detected in the cingulum bundle in the perinatal rat models of hypoxia and growth restriction developed by Verney and collaborators [112–114].
In mammals, the numerous cortical astrocytes are reported to be mainly generated not only from radial glial cells but also from other cell types that are not clearly elucidated such as progenitors in the SVZ [62]. Human astrocytes are far more complex in diversity and size, and the ratio of glia to neuron is higher when compared to rodent [115]. The protoplasmic and fibrous astrocytes appeared in waves in the cortical anlage [115], begin to differentiate around midgestation and co-expression between vimentin and GFAP is observed [116]. Functional astrocytes evolve in parallel with the maturation of the vascular endothelial cells involved in blood-brain barrier (BBB) formation [68, 117]. During development, monocarboxylates including lactate represent a major source of energy for the developing neurons [118]. The expression of monocarboxylate transporters such as MCT1 confirms the functionality of astrocytes in the energy trafficking occurring in the human visual cortex from GW19 [119].
Here, we provide a schematic drawing (Figure 4) comparing the schedule for the different key events occurring during the cortical development in human and in rat.

Figure 4.
Presumptive comparative schedule for development of the cerebral cortex in rat and human.
3. Sources of serotonin to the mammalian cortex
3.1. Serotonin synthesis and degradation
Serotonin is synthesized from the essential amino acid tryptophan. In the blood stream, tryptophan is linked to serum albumin but a proportion that decreases with age is free to cross the BBB (10% at post-natal day 12 when BBB is thought fully functional [120]). Tryptophan is then transported, accumulated in 5-HT-producing cells and hydroxylated by the tryptophan hydroxylase enzymes (Tph). Tryptophan hydroxylase type 2 (Tph2) is expressed in serotoninergic neurons of the raphe nuclei and myenteric neurons [121, 122], while Tph1 is expressed in the pineal gland, in the placenta and in various peripheral tissues [18, 19, 122, 123]. 5-hydroxytryptophan is then further decarboxylated into 5-HT by the aromatic amino acid decarboxylase (AADC). The availability of tryptophan to synthesise 5-HT depends on the inflammatory status of the organism. In case of inflammation, indoleamine 2,3-dioxygenase (IDO) is generated, which can lead to 5-HT depletion in the organism [35].
5-HT is catabolized by monoamine oxidases A or B (MAOA or MAOB [124, 125]). MAOA has higher affinity for 5-HT than MAOB and is strongly co-expressed with MAOB between E12 to P7 in rodent serotoninergic neurons [126]. After P7, the expression of MAOB is largely predominant in 5-HT+ neurons [126]. MAOs are also expressed by many non-aminergic structures, in particular the placenta and in a subpopulation of VZ-SVZ cells ([126, 127] and our unpublished results) where they may regulate the amount of 5-HT locally. Interestingly, MAOs expression and protein synthesis are tightly regulated and have been shown to be sensitive to environmental factors such as inflammation and ischaemia-like conditions [34].
During embryonic development, the telencephalon receives 5-HT arising from multiple sources that are mainly of extra-embryonic or maternal origin at the beginning of gestation. Later, they progressively arise from different embryonic regions. Below, we will briefly recapitulate the sources of serotonin provided to the embryonic telencephalon in relation with cortical development.
3.2. Development of the serotoninergic neurons and projections
In mammals, brainstem serotoninergic neurons are subdivided into 9 groups (B1–B9) forming a caudal and a rostral division. The rostral division (B5–B9; including the dorsal (B6, B7) and median raphe nuclei (B5, B8)) projects to the forebrain [65, 128, 129] (Figure 1B). Since these initial descriptions, recent mapping of 5-HT projections have been performed in mice revealing a higher level of refinement in the projections of raphe clusters towards specific targets [130]. Such level of analysis is lacking in primate and human.
In mice, the rostral division differentiates by E10-E11 (E12-E15 in rats); dorsal and median raphe send axons that reach the cortico-striatal junction by E14 in mice before entering the cortical anlage as two tangential streams, one above and the other below the CP [131, 132]. In the MZ, C-R cells and serotoninergic axons are in close apposition and make transient synaptic contacts [133, 134]. Below the CP, 5-HT afferents are mainly restricted to the IZ and the SP [131]. By E16-E17 in mice, thalamocortical axons (TCAs) invade the cortical anlage and are in close apposition with 5-HT axons running in the IZ. At the end of corticogenesis, 5-HT axons gradually arborize, sending numerous branches into the CP [131].
By P21, serotoninergic axons become evenly distributed in the different cortical territories showing their mature pattern of innervation [128]. Dorsal raphe axons are generally thin with pleiotropic varicosities that preferentially arborize in cortical layers IV and V. By contrast, median raphe axons show large spherical varicosities, form true chemical synapses, preferentially arborize in layer I and lower white matter, and contact interneurons containing VIP and cholecystokinin (CCK) [64, 65, 135] (Figure 1). Thus, 5-HT could be released along the entire axonal network through volume transmission or in synaptic clefts.
Anatomical studies have described the primate raphe nuclei and the serotonergic cortical innervation at mature stages [136–138], but only a few studies have reported their development. In Rhesus monkey, the genesis of raphe neurons was detected in the first quarter of gestation (E28-E45, birth: E165) [139] and 5HT+ fibres were reported in the entorhinal cortex at E70, similarly to tyrosine-hydroxylase+ catecholaminergic axons [140]. In human cortical anlage, one can suggest that the early afferents of serotoninergic axons as described for the catecholaminergic afferents may penetrate the cortical anlage around GW8 and invade the fetal cortex at midgestation in a mature-like pattern [102, 141]. In parallel, SERT expression in developing TCAs have been detected at GW10 in human cortical anlage [142]. Comparable expression has been described for the visual sensory system in the marmoset [143].
3.3. Other sources of serotonin
The first demonstrations showing that 5-HT was influencing very early embryonic development were provided by pioneer groups showing that

Figure 5.
Maternal, placental, genetic and pharmacological conditions determining the amount of serotonin supply to the developing telencephalon. Tryptophan is provided to the embryo but could also be converted into 5-HTP (5-hydroxytryptamine) or further into serotonin (5-HT) in the placenta via the expression of various metabolic enzymes expressed in the placenta. In addition, 5-HT from maternal sources could be taken up by the placenta that also expressed serotonin transporter (SERT). During early embryonic stages 5-HT could be delivered directly to the developing embryo. After E15-E16, when 5-HT axons of the hindbrain reach the cortex, 5-HT could act on various target cells (Cell) expressing selected arrays of 5-HT receptors. At this stage 5-HT could also be taken up and stored by thalamocortical afferents (TC) and released after specific stimulation. In addition 5-HTP is provided to the (tryptophan hydroxylase type 2) Tph2 and the (aromatic amino acid decarboxylase) AADC containing neurons that synthetize 5-HT. In this drawing adapted from [19], we have pointed in the large left arrow the maternal conditions that are best known to interfere with 5-HT availability to the embryo. We have also indicated that inhibitors of 5-HT uptake (SSRIs) that cross all barriers affect SERT function at all levels. Genetic polymorphisms or methylations mentioned in the text are indicated by a star. The major catabolic enzymes of 5-HT, monoamine oxidases are indicated (MAO). Tryptophan hydroxylase type 1; Tph1.
Several groups have suggested that, at early stages, 5-HT arises from maternal sources. Indeed, this was suggested when analysing the phenotype of embryos generated from Tph1+/− or Tph1+/+ mothers. Tph1−/− and Tph1+/− embryos obtained from crosses between heterozygous parents were indistinguishable from their wild-type littermates (the crown-rump length (CRL) was of 7.4–7.5 mm). By contrast, 80–88.9% of Tph1−/− and Tph1+/− embryos born Tph1−/− mothers displayed low CRL values (5.8–7.4 mm). This suggests that the partial lack of maternal 5-HT provided to the embryo may be sufficient to explain some of the littermates phenotypes [18, 123].
Recently, the placenta (that is of embryonic origin) has been identified as an important source of 5-HT for the developing embryo. The placenta (syncytiothrophoblastic cells and sinusoidal throphoblastic giant cells) of the placenta contain Tph1, AADC and MAO [124, 125, 127], and convert tryptophan of maternal origin into 5-HT as soon as E10-E11 [150]. Homozygote knock-out embryos in which 5-HT neurons fail to fully differentiate or to produce normal amounts of 5-HT levels do not display severe cortical defects when gestating in heterozygous dams. Examples include mice lacking the transcription factors Lmx1b [151] or Pet-1 [152], in which all or 70–80% of 5-HT raphe neurons fail to develop, and mice lacking Tph2 [153, 154]. Further analysis revealed that Pet-1 knock-out embryos developing in heterozygous dams have normal 5-HT levels before the closure of the BBB (before E15 [68]). These studies suggest that 5-HT produced by the placenta may buffer maternal deficiency. However, the compensatory mechanisms remain to be clarified.
Outside the CNS, 5-HT is also produced in the periphery of the developing embryo: from the myenteric plexus (from E15-E16), from enterochromaffin cells of the lining lumen of the digestive tract (from E18), from neuroepithelial cells of the respiratory tracts, from the parafollicular cells of the thyroid and from pinealocytes (belonging to the CNS; from E12). 5-HT could also be taken up by SERT expressing cells and further delivered to a distant region. SERT is expressed in platelets and mast cells [155, 156] that become numerous around E12 in mice. These cells could cross the BBB, transit across blood vessels that start to invade the developing cortex by E10-E11 in mice [68]. Whether these structures and mechanisms provide substantial amount of 5-HT to the developing telencephalon remains to be clarified.
Transiently, sensory thalamic neurons express SERT (E15-P15 in mice) and the vesicular monoamine transporter type 2 (VMAT2) that are respectively responsible for the uptake and packaging of 5-HT into synaptic vesicles [37, 157, 158]. Sensory thalamic neurons do not contain MAOs [159] but are equipped to release 5-HT, possibly with other transmitters (e.g. glutamate), after specific stimulation (review in Ref. [15]). Interestingly, it has been suggested that thalamocortical axons (TCAs) could be implicated in the proliferation and migration of glutamatergic neurons [160, 161] in addition to their well-known role on axonal refinement (see below).
Tryptophan is provided to the embryo but could also be converted into 5-hydroxytryptamine (5-HTP) or further into serotonin (5-HT; violet) in the placenta via the expression of various metabolic enzymes expressed in the placenta. In addition, 5-HT from maternal sources could be taken up by the placenta that also expressed serotonin transporter (SERT). During early embryonic stages, 5-HT could be delivered directly to the developing embryo. After E15-E16, when 5-HT axons of the hindbrain reach the cortex, 5-HT could act on various target cells (Cell; maroon) expressing selected arrays of 5-HT receptors. At this stage, 5-HT could also be taken up and stored by thalamocortical afferents (TC) and released after specific stimulation. In addition, 5-HTP is provided to the tryptophan hydroxylase type 2 (Tph2) and the aromatic L-amino acid decarboxylase (AADC) containing neurons that synthesize 5-HT. In this drawing adapted from Ref. [19], we have pointed in orange the maternal conditions that are best known to interfere with 5-HT availability to the embryo. We have also indicated that inhibitors of 5-HT uptake (SSRIs) that cross all barriers affect SERT function at all levels. Genetic polymorphisms or methylations mentioned in the text are indicated by a star. The major catabolic enzymes of 5-HT, monoamine oxidases (MAO) are indicated.
4. Serotonin receptors with specific attention to the 5-HT3A
4.1. Transducing pathways
At least fourteen genes encoding for 5-HT receptors have been identified and cloned in the mammalian brain [162–165]. In addition, isoform diversity, alternative splicing of some subtypes and RNA editing add to the diversity of serotoninergic receptors. With the exception of the 5-HT3 receptors, all 5-HT receptors are coupled to G-proteins. According to their second messenger coupling pathways, 5-HT receptors have been categorized into four groups. The 5-HT1 and 5-HT5 receptors are coupled to Gi/Go proteins and exert their inhibitory effects on adenylate cyclase, inhibiting cAMP formation. The 5-HT2 receptors are coupled to Gq proteins and stimulate phospholipase C to increase the hydrolysis of inositol phosphates and elevate intracellular Ca2+. The 5-HT4,6,7 receptors are coupled to Gs proteins and are positively linked to adenylate cyclase and increase cAMP formation. 5-HT3 receptors belong to a family of ligand-gated ion channel receptors that include nicotinic acetylcholine receptors, GABAA receptors and glycine receptors and are modulated by intracellular cyclic AMP [162]. The 5-HT3 receptors respond to neurotransmitter release via direct (through the 5-HT3 receptor itself) or indirect activation of the voltage-gated Ca2+ channels and lead to Ca2+ entry into the cell [166]. 5-HT3 receptors are composed of five subunits, with the majority being homomers of 5-HT3A receptors. Heteromeric 5-HT3AB receptors have been observed in specific brain regions and display lower Ca2+ permeability than the homomeric 5-HT3A receptors [167–169].
4.2. Expression patterns
Despite the efforts of many laboratories and open databases, a complete description of the developmental expression pattern of 5-HT receptors in the cerebral cortex is still lacking in rodent and very few studies have been performed in primate. However, pictures are emerging in the rodent brain. For example, 5-HT1A,F are expressed in neocortical proliferative zones in E14.5 rodent brain [17] and the 5-HT2B are expressed in the proliferative zones of the human occipital cortex [129] and in all microglial cells [170, 171]. The 5-HT1A,B,D, 5-HT2A, 5-HT2C and 5-HT3A, are expressed in specific subpopulations of post-mitotic neurons [17, 88, 91, 167, 168, 172, 173], whereas the 5-HT6 is expressed in both migrating interneurons and pyramidal neurons [174, 175].
The dynamic expression pattern of the 5-HT3A receptor has been described in details recently in mice. In the developing cortex, 5-HT3A is expressed as early as E11-E12 in neurons expressing reelin (Cajal-Retzius cells) and/or GABA cells located in the PP [88, 173]. The 5-HT3A is expressed by newly post-mitotic GABAergic neurons located in the CGE and AEP/PO, where about 30% of cortical GABAergic neurons are generated ([52, 88]; see Figure 3A and
5. Impact of serotonin imbalance on cortical circuit assembly
5.1. Serotonin and cell proliferation
It has been postulated for some time that 5-HT regulates the proliferation of a wide variety of cell types including cortical neurons. Pharmacological studies inducing depletion of several monoamines triggered drawbacks due to the non-selectivity of the drugs used and they will not be discussed here.
Recently, transgenic models selectively targeting specific serotonin-related genes in different neuronal populations have started to provide more insights. For instance, mice deficient in Tph1 or Tph2 showed body weight reduction and delayed maturation of cortical layers [18, 153, 177]. Heterozygous embryos growing in null mutant Tph1−/− mice showed an average of 30% reduction in proliferating cells (BrdU+) in the VZ after a 2 h pulse of BrdU administration, an analog of thymidine that is incorporated during the S phase of the cell cycle [18]. Although these studies suggest that 5-HT from Tph1+ sources may regulate the proliferation of neuronal precursors, additional studies are needed to refine these observations.
Hyposerotonin-induced microcephaly could also be due to increased death of post-mitotic neurons or neuronal progenitors. Indeed, 5-HT2 stimulation promotes the survival of glutamatergic neurons
The analysis of mice lacking MAOA and B, which displays high 5-HT levels but normal dopamine and norepinephrine levels during development, revealed a specific reduction of symmetric divisions of intermediate precursors cells [76] in SVZ during late corticogenesis (E17.5) [182]. This unexpected alteration was reverted after pharmacological inhibition of 5-HT synthesis (with p-chlorophenylalanine; PCPA) between E14.5-E19.5. In addition, neurosphere formation was modulated by 5-HT in a dose-dependent manner
During early development, 5-HT could also promote gap junction coupling through 5-HT2 stimulation [183] that coordinates cell-cell assembly during cell cycle [184].
5.2. Serotonin and neuronal migration
In most phyla, 5-HT triggers motility of various cell types including vertebrate lymphocytes (chick, fish, rodent [185, 186]) and microglia towards the CNS [170]. In the mammalian cortex, a role for 5-HT in regulating the migration of cortical neurons has recently emerged. In this context, 5-HT produces opposite consequences depending on its concentration.
One of the first experiments to address this question was made

Figure 6.
Modulation of cerebral circuit formation by 5-HT3A A, 5-HT3A (3A) is expressed by migrating interneurons generated in the caudal ganglionic eminence (CGE). Physiological concentration of serotonin (5-HT), induce an acceleration of the radial migration of 5-HT3A+ interneurons at E17. B, At early postnatal stage, Cajal-Retzius cells (C-R) that express 5-HT3A, respond to 5-HT application by releasing reelin that through the activation of the integrin signaling pathway induce pruning of apical dendrites of pyramidal neurons (Pyr). This figure is adapted from [
Although dynamic expression pattern of 5-HT receptors is lacking in developing primate and human cortex, a very recent study by the group of Alvarez-Bulla showed that in human, late-born interneurons continue to migrate in the cingulate cortex even after birth. These interneurons expressed a combination of transcription factors and a substantial fraction of them expressed COUP-TFII or SP8 (22 or 28% respectively) that are mainly specific of 5-HT3A+ interneurons suggesting that 5-HT could also modulate the migration and positioning of these neurons in human [97]. Interestingly, in the primate cortex, it was shown that 5-HT3A is expressed by a subset of small GABA+, substance P+ or calbindin+ neurons and by medium-size CR+ neurons [190].
By contrast, 5-HT excess appears to have opposite role on migrating neurons. Using high dosage of 5-HT
5.3. Serotonin and differentiation of cortical neurons and afferents
Lauder and Krebs were the first to report that depletion of 5-HT delayed the cessation of cell division, a marker of cell differentiation [144, 192]. After these pioneering studies, numerous groups have shown that 5-HT can influence dendritic and axonal morphogenesis during cortical development.
5.3.1. Serotonin and dendritic maturation of cortical neurons
5-HT was shown to regulate the physiology of C-R cells known to be key regulators of various aspects of cortical development including dendritic arborization. This role is largely mediated by the secretion of the glycoprotein, reelin [72, 74]. C-R cells receive serotoninergic projections with which they make transient synaptic contacts [134] and reelin secretion was shown to be regulated in part by the amount of brain 5-HT. Pharmacological perturbation of the serotoninergic system by 5-methoxytryptamine (a non-selective 5-HT receptor agonist) reduces reelin levels circulating in the blood flow at P0 [134], leading to the formation of abnormal micro-columns in the mice P7 presubicular cortex, a feature that is observed in autistic syndromes (ASDs). The activation of C-R cells was proposed to be modulated by 5-HT1A or by the 5-HT3A receptors, as they were both suspected to be expressed in the marginal zone during development [167, 193]. Interestingly, the 5-HT3A has been shown to be expressed by C-R cells (averaging 80% at P0) and the synaptic activation of 5-HT3A was shown to be sufficient to induce action-potential firing on C-R cells suggesting that 5-HT3A could play a role in dendritic development [173]. The contribution of the 5-HT3A was further analysed. The deletion or blockade of 5-HT3A receptors was shown to induce excessive arborization of layers II-III apical dendrites of pyramidal neurons. Application of the N-terminal region of reelin, that induces the activation of a signalling pathway that is independent from the classic ApoER2/VLDL-pathway, rescued the dendritic phenotype of cortical pyramidal neurons in 5-HT3A:KO cortical slices, whereas reelin blockade leads to an increased growth of apical dendrites ([173]; see Figure 6B). This study suggested that increased reelin secretion due to over-activation of the 5-HT3A receptor could induce a decreased growth of apical dendrites. Interestingly, fluoxetine (an inhibitor of 5-HT uptake, SSRI) administration from E8 to E18 decreased the dendritic basal and apical arbor complexity of layer II/III pyramidal neurons in the somatosensory cortex. Such a role is specific to a selective developmental period and SSRIs have opposite functions at mature stages [194]. Furthermore, the effects of SSRIs on developing dendrites were abolished when administered in the 5-HT3A:KO mice or after pharmacological blockade of the 5-HT3A receptor [173, 195]. Moreover, the fine tuning of 5-HT3A signalling has been shown to be responsible for the anxiety-like behaviours that are induced by prenatal fluoxetine treatment in wild type mice [196]. These results suggest that developmental excess of serotonin increases reelin secretion by over-activating 5-HT3A receptors expressed on C-R cells, consequently inhibiting dendritic growth of pyramidal neurons. Whether 5-HT3A+ interneurons participate in this process remains unclear.
Animals fed with low tryptophan diet [197, 198] display cortical pyramidal neurons with decreased dendritic complexity and spine density. Thus, 5-HT may regulate dendritic maturation and spine density through different types of 5-HT receptors that remain to be identified. In this respect, the 5-HT1A is strongly expressed in the developing cortical plate [17] and is known to be necessary for the dendritic maturation of CA1 pyramidal neurons [199]. The 5-HT6 receptor also appears as a good candidate for controlling neuritic and dendritic development due to its ability to engage signalling pathways (e.g. Fyn, mTOR and Cdk5) playing roles in these processes.
5.3.2. Serotonin and axonal development within the cerebral cortex
The first clear demonstration that serotonin acts on cellular processes involved in the formation of cortical circuits comes from works performed on the rodent barrel field in the somatosensory cortex (S1). The serendipitous generation of a mouse displaying deficiency in the gene encoding for MAOA was at the starting point of these discoveries. These studies showed that excessive 5-HT amounts (ninefold increase at P0) in the developing cortex induced an abnormal organization of thalamocortical afferents (TCAs) growing in the layer IV of the primary somatosensory cortex [36, 37]. These alterations were later interpreted as an abnormal refining of TC axons due to a specific rise of 5-HT occurring during a sensitive period (P0-P4: [201]). In addition, pharmacological normalization of 5-HT levels in MAOA:KO mice by P0-P4 PCPA-treatment was sufficient to revert to normal the organization of S1 in MAOA:KO mice [37]. Later, it was shown that genetic SERT deficiency affected S1 organization similarly in rodent. These alterations are not only structural but also impair whisker-mediated perception [10]. Hyper-activation of the 5-HT1B receptor, transiently expressed on TCAs during development, plays a key role in this process. Indeed, SERT:KO and MAOA:KO mice that are deficient in 5-HT1B receptors are rescued [202–205]. Interestingly, serotonin excess does not only impairs S1 organization, but also such a role could probably be generalized in other regions displaying transient 5-HT uptake [158] as this was shown for the visual system [202, 205, 206]. Moreover, such a role could also occur in primate cortex since SERT is transiently expressed in the visual sensory thalamic neurons, at least in the marmoset [143]. So far due to the difficulty to obtain human embryonic samples of late stages, clear sets of data are still lacking but numerous non-serotoninergic fibres, presumably TCAs, labelled by SERT have been detected at GW10 [142].
Surprisingly, perinatal 5-HT deficiency only induces a reduction of barrel field organization without altering its general organization [177, 207, 208]. Nevertheless, further studies need to be carried since early reduction of 5-HT during embryonic development induces the emergence of altered behaviour [153].
Other studies suggest a prenatal role for 5-HT in regulating initial TCAs pathfinding. TCAs express SERT, 5-HT1B and 5-HT1D receptors at a time when TCAs are navigating towards the pallium. Embryonic down-regulation of 5-HT1B/C receptors in TCAs using
5.4. Serotonin and the regulation of astrocytes and microglial cell functions
Astrocytes and microglial cells have been shown to be implicated in key processes—from neurogenesis to synaptogenesis—involved in cortical development (for review, see Ref. [61]). These cells bear several 5-HT receptors depending on their stage and state (resting or activated) making 5-HT an indirect actor of cortical development via the modulation of their functions [170]. Pioneer studies have shown that 5-HT1A and 5-HT2 are expressed by both immature and mature astrocytes in human and rodent cortex, and that 5-HT stimulates the release of several trophic factor produced by glial cells that promote neuritic extension and synaptogenesis of cortical and serotoninergic neurons such as S100β or BDNF. Conversely, lesions of the serotoninergic system were shown to increase GFAP and to decrease the release of several trophic factors [210, 211].
More recently, several groups have focused their attention on the implications of microglial cells that colonize the embryonic telencephalon at the very beginning of its formation in rodent and human (see above; [63, 212]). Through local phagocytic activities and the release of various molecules (such as interleukin-1beta or tumor necrosis factor-alpha), microglial cells have been shown to regulate neurogenesis, to participate in axonal and dendritic organizations and pruning [212–216]. From early stage of colonization, microglial cells have been shown to express, at least, the 5-HT2B receptor and at later stages or upon stimulation (such as inflammation), several other 5-HT receptors have been detected in rodent (5-HT1F,2A,2B,3B,5A and 5-HT7; [170]). The activation of these receptors has been shown to regulate their motility, their phagocytic properties and selective reshaping of axonal and dendritic arborizations. For instance, 5-HT2B has recently been shown to induce synaptic refinement of retinal projections to the thalamus since this process is impaired in mice lacking 5-HT2B selectively in microglial cells [171].
6. Serotonin imbalance and consequences in human pathology
6.1. Serotonin imbalance and 5-HT3 receptor modulation in human pathology
Developmental imbalance of 5-HT homeostasis or serotonin receptor signalling impacts various processes involved in the formation of cortical circuits and has consequences on the emergence of abnormal behaviour in rodent. Some similarities have been detected in primate and human but many aspects remain to be tested, in particular, the cellular processes implicated (conditioned by SERT or 5-HT receptors expressions) and the time windows of vulnerability.
In human, three major causes of 5-HT imbalance leading to psychiatric diseases have been clearly identified: abnormal metabolism of 5-HT, exposure of fetuses to SSRIs and genetic inheritance of SERT variants (these points of vulnerability have been indicated in Figure 5). Following the discovery of the lack of MAOA in Norrie disease [217], abnormal regulation of the enzymes implicated in 5-HT metabolism has been known for long to be associated with neuropsychiatric diseases (recently reviewed by Naoi et al. [218]). However, it is not known whether the alteration in prenatal or post-natal human life induces such illness. Pharmacological SSRIs treatment gave clearer answers. Indeed, SSRIs during pregnancy are still largely used among women ((2–13%) [219]); despite the high incidence of mood disorders in pregnant women (around 20% of pregnant women are affected) and the deleterious effect of maternal stress on fetal development. However, SSRIs crossing the placenta, are detectable in breast milk, reach the developing brain. Both, short-term (e.g. fetal cardiovascular malformations) and long-term drawbacks of the treatments have been revealed (see below). During gestation, SSRIs induced a reduction of blood flow in the middle cerebral artery at GW36 [220] and reduced fetal head growth [221]. SSRIs induce reduced motor movements and altered speech perception at 6–10 months of age, increased irritability, and persistent blunted pain reactivity [222, 223]. Children exposed to SSRIs during pregnancy have poor scores on psychomotor developmental scales [224] and higher risks to develop autism spectrum disorders [225]. The risk appeared higher when exposure to SSRIs occurred during the second trimester and with higher dosage of SSRIs, suggesting deleterious effects on early neural circuit formation. The third well-known cause of excessive 5-HT-signalling in human is of genetic origin. There are two variants of SERT alleles leading to different levels of SERT expression: the short form that induces decreased levels of SERT expression and SERT hypofunction [41] and the long form. Hypofunctional s-allele has been shown to increase the risk for a wide range of psychopathological traits. When combined with maternal anxiety during pregnancy, infants and children carrying the s-allele showed higher levels of negative emotionality compared to l-allele carriers [42] and increased scores of anxiety and depression [43, 226]. Interestingly, platelets that bear SERT (generally accepted to be identical to neuronal SERT), VMAT2 and 5-HT2 receptors have been suspected to play a role in the emergence of autistic disease in human. Dysregulation in platelets function has been largely used as a marker of autism, however clarifications need to emerge from further studies (for review, see Refs. [227, 228].
Although the consequences are subtle, they reveal that both genetic and environmental SERT deficiency impact human development and increase the risks of future psychiatric diseases [229, 230]. Overall, these findings point to the general conclusion that various clinical pathological traits, including autism, depression and anxiety-related phenotypes are associated to conditions of SERT deficiency during development. One should also consider that alteration of other genes may have synergistic effect on the emergence of those diseases or by contrast that bearing allelic variants of other genes could dampen the negative effects of SSRIs [231].
Rodent studies have revealed that the 5-HT3A regulates cellular events involved in cortical circuit formation (see above). Human genetic studies have recently explored more deeply the involvement of 5-HT3A polymorphisms and methylation in the emergence of various pathological traits and they now provide compelling evidence for such a role. In human genetic studies, it has been shown that a single-nucleotide polymorphism in 5-HT3A (SNP; rs1062613) was associated with bipolar disease [232]. Moreover, allelic variants or specific levels of methylation of the 5-HT3A have been shown to be tightly linked with alcohol-dependence, modulation of emotional networks and increase of depressive-related symptoms [233]. The emergence of depressive-like diseases was associated at the structural level with a decreased grey matter in the fronto-limbic region. Interestingly, 5-HT3A has been shown to interact with the brain-derived neurotrophic factor, a key factor for circuit formation and consolidation [234, 235]. Thus, genetic polymorphism or methylation of 5-HT3A appears as a marker of susceptibility to develop a large panel of diseases.
Together, this further confirms complex connections between early-life stress and the serotoninergic systems.
6.2. Linking serotoninergic system and neonatal inflammation/ischaemia with the emergence of neuropsychiatric diseases in children and adults
Early-life inflammation modulates adulthood-inflammatory response [236]. In early brain injuries, activation of the immune system during fetal and neonatal life affects critical phases of brain development, with long-lasting consequences for neurological and mental health [237]. Neonatal stroke, systemic infection, or excitotoxicity/hypoxia-ischaemia (see Figure 5) induce perinatal insults activating the immune system and trigger peripheral and central responses that involve immune mediators (cytokines and chemokines), reactive oxygen species (ROS), reactive nitrosative species, excitotoxicity, mitochondrial impairment, and vascular integrity. In general, neonatal encephalopathy is of complex aetiology, encompassing several causal events, with strong evidence of fetal exposure to infection. The complex and multifactorial process of perinatal brain injury involves sensitization, whereby factors not severe enough by themselves to induce significant brain damage make the developing brain more susceptible to a second insult [238]. Substantial numbers of preclinical studies have demonstrated the sensitizing effects of gestational or neonatal systemic inflammation, gestational chronic mild maternal stress, and gestational hypoxia on perinatal excitotoxic or hypoxic-ischaemic lesions. Genetic factors have also been shown to influence the developing brain's response to sensitizing factors. Efforts to design therapies aimed to reduce the sensitizing effects of inflammation have been undertaken as neuroprotective agents, such as therapeutic hypothermia which have been performed mainly in models of pure hypoxia-ischaemia [238]. One of the main alterations following perinatal infection/inflammation is a persistent low-grade inflammation characterized by higher expression of inflammatory mediators and also microglial reactivity during adulthood [236]. Adult rodent exposed during early-life to LPS-enhanced expression of CD11b, IL-1β and IL-6 and also more activated microglia in the hippocampus, the striatum and substantia nigra/ventral tegmental area [239, 240]. This persistent low-grade inflammation sensitizes the brain to secondary injuries, which can lead to neurological disorders such as cerebral palsy, mood disorder, schizophrenia, or Parkinson disease [241].
Serotoninergic central system is vulnerable following a neonatal hypoxic-ischemic insult induced in a rat model [242] with a significant reduction in 5-HT levels, 5-HT transporter expression and 5-HT+ neurons is the dorsal raphe, 6 weeks after insult compared to control animals. Inhibition of neuroinflammation by Minocycline within the first week after injury is sufficient to prevent long-term neuroinflammation as well as serotonergic system damage still. The loss of dorsal raphe 5-HT+ neurons has been suspected to be induced by an alteration of one of their major target tissues: the prefrontal cortex [243].
7. Conclusion and perspectives
Both genetic and environmental factors that influence serotonin signalling during specific sensitive periods of development impact specific cellular events involved in the development of cortical circuits. Such alterations depending on the cellular target and the time of occurrence could result in a predisposition to a large spectrum of cognitive or psychiatric illnesses including autism and depression.
Acknowledgments
The work was supported by the INSERM. We warmly thank Pierre Gressens for his kind support, Stephane Peineau for kindly helping us with informatics and softwares and Zsolt Csaba for carefully reading and correcting our manuscript. T.V. thanks Hervé Langzam for fruitful discussions.
References
- 1.
Peters A, Kara DA. The neuronal composition of area 17 of rat visual cortex. II. The nonpyramidal cells. Journal of Comparative Neurology. 1985; 234 (2):242-263 - 2.
Peters A, Kara DA. The neuronal composition of area 17 of rat visual cortex. I. The pyramidal cells. Journal of Comparative Neurology. 1985; 234 (2):218-241 - 3.
Baraban SC, Tallent MK. Interneuron Diversity series: Interneuronal neuropeptides – endogenous regulators of neuronal excitability. Trends Neurosciences. 2004; 27 (3):135-142 - 4.
Ascoli GA, et al. Petilla terminology: Nomenclature of features of GABAergic interneurons of the cerebral cortex. Nature Reviews Neuroscience. 2008; 9 (7):557-568 - 5.
DeFelipe J, et al. New insights into the classification and nomenclature of cortical GABAergic interneurons. Nature Reviews Neuroscience. 2013; 14 (3):202-216 - 6.
Kettenmann H, Kirchhoff F, Verkhratsky A. Microglia: New roles for the synaptic stripper. Neuron. 2013;77(1):10-18 - 7.
Krencik R, van Asperen JV, Ullian EM. Human astrocytes are distinct contributors to the complexity of synaptic function. Brain Research Bulletin. 2017; 129 :66-73 - 8.
Marin O. Interneuron dysfunction in psychiatric disorders. Nature Reviews Neuroscience. 2012; 13 (2):107-120 - 9.
Stolp H, et al. The long and the short of it: Gene and environment interactions during early cortical development and consequences for Long-Term neurological disease. Front Psychiatry. 2012; 3 :50 - 10.
Kinast K, et al. Genetic and pharmacological manipulations of the serotonergic system in early life: Neurodevelopmental underpinnings of autism-related behavior. Frontiers in Cellular Neuroscience. 2013; 7 :72 - 11.
Wonders CP, Anderson SA. The origin and specification of cortical interneurons. Nature Reviews Neuroscience. 2006; 7 (9):687-696 - 12.
Rakic P. Evolution of the neocortex: A perspective from developmental biology. Nature Reviews Neuroscience. 2009; 10 (10):724-735 - 13.
Budday S, Steinmann P, Kuhl E. Physical biology of human brain development. Frontiers in Cellular Neuroscience. 2015; 9 :257 - 14.
Nowakowski TJ, et al. Transformation of the radial glia scaffold demarcates two stages of human cerebral cortex development. Neuron. 2016; 91 (6):1219-1227 - 15.
Gaspar P, Cases O, Maroteaux L. The developmental role of serotonin: News from mouse molecular genetics. Nature Reviews Neuroscience. 2003; 4 (12):1002-1012 - 16.
Vitalis T, et al. Developmental expression pattern of monoamine oxidases in sensory organs and neural crest derivatives. Journal of Comparative Neurology. 2003; 464 (3):392-403 - 17.
Bonnin A, et al. Expression mapping of 5-HT1 serotonin receptor subtypes during fetal and early postnatal mouse forebrain development. Neuroscience. 2006; 141 (2):781-794 - 18.
Cote F, et al. Maternal serotonin is crucial for murine embryonic development. Proceedings of the National Academy of Sciences of the United States. 2007; 104 (1):329-334 - 19.
Bonnin A, Levitt P. Fetal, maternal, and placental sources of serotonin and new implications for developmental programming of the brain. Neuroscience. 2011; 197 :1-7 - 20.
Vitalis T, Rossier J. New insights into cortical interneurons development and classification: Contribution of developmental studies. Developmental Neurobiology. 2011; 71 (1):34-44 - 21.
Berger-Sweeney J, Hohmann CF. Behavioral consequences of abnormal cortical development: Insights into developmental disabilities. Behavioural Brain Research. 1997; 86 (2):121-142 - 22.
Levitt P, et al. New evidence for neurotransmitter influences on brain development. Trends Neurosciences. 1997; 20 (6):269-274 - 23.
Bonnin A, et al. The SSRI citalopram affects fetal thalamic axon responsiveness to netrin-1 in vitro independently of SERT antagonism. Neuropsychopharmacology. 2012; 37 (8):1879-1884 - 24.
Lesch KP, Waider J. Serotonin in the modulation of neural plasticity and networks: Implications for neurodevelopmental disorders. Neuron. 2012; 76 (1):175-191 - 25.
Velasquez F, et al. The influence of 5-HTTLPR transporter genotype on amygdala-subgenual anterior cingulate cortex connectivity in autism spectrum disorder. Developmental Cognitive Neuroscience. 2016; 24 :12-20 - 26.
Brummelte S, et al. Developmental changes in serotonin signaling: Implications for early brain function, behavior and adaptation. Neuroscience. 2017; 342 :212-231 - 27.
Serfaty CA, et al. Nutritional tryptophan restriction and the role of serotonin in development and plasticity of central visual connections. Neuroimmunomodulation. 2008; 15 (3):170-175 - 28.
Yano JM, et al. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell. 2015; 161 (2):264-276 - 29.
Papaioannou A, et al. Effects of neonatal handling on basal and stress-induced monoamine levels in the male and female rat brain. Neuroscience. 2002; 114 (1):195-206 - 30.
Papaioannou A, et al. Sex differences in the effects of neonatal handling on the animal's response to stress and the vulnerability for depressive behaviour. Behavioural Brain Research. 2002; 129 (1-2):131-139 - 31.
Provenzi L, et al. SLC6A4 methylation as an epigenetic marker of life adversity exposures in humans: A systematic review of literature. Neuroscience & Biobehavioral Reviews. 2016; 71 :7-20 - 32.
Winter C, et al. Dopamine and serotonin levels following prenatal viral infection in mouse – implications for psychiatric disorders such as schizophrenia and autism. European Neuropsychopharmacology. 2008; 18 (10):712-716 - 33.
Winter C, et al. Prenatal immune activation leads to multiple changes in basal neurotransmitter levels in the adult brain: Implications for brain disorders of neurodevelopmental origin such as schizophrenia. International Journal of Neuropsychopharmacology. 2009; 12 (4):513-524 - 34.
Gupta V, et al. Molecular mechanism of monoamine oxidase A gene regulation under inflammation and ischemia-like conditions: Key roles of the transcription factors GATA2, Sp1 and TBP. Journal of Neurochemistry. 2015; 134 (1):21-38 - 35.
Miller AH, Raison CL. Are Anti-inflammatory therapies viable treatments for psychiatric disorders?: Where the rubber meets the road. JAMA Psychiatry. 2015; 72 (6):527-528 - 36.
Cases O, et al. Aggressive behavior and altered amounts of brain serotonin and norepinephrine in mice lacking MAOA. Science. 1995; 268 (5218):1763-1766 - 37.
Cases O, et al. Lack of barrels in the somatosensory cortex of monoamine oxidase A-deficient mice: Role of a serotonin excess during the critical period. Neuron. 1996; 16 (2):297-307 - 38.
Popa D, et al. Lasting syndrome of depression produced by reduction in serotonin uptake during postnatal development: Evidence from sleep, stress, and behavior. Journal of Neurosciences. 2008; 28 (14):3546-3554 - 39.
Ansorge MS, et al. Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice. Science. 2004; 306 (5697):879-881 - 40.
Ansorge MS, Morelli E, Gingrich JA. Inhibition of serotonin but not norepinephrine transport during development produces delayed, persistent perturbations of emotional behaviors in mice. Journal of Neurosciences. 2008; 28 (1):199-207 - 41.
Murphy DL, Lesch KP. Targeting the murine serotonin transporter: Insights into human neurobiology. Nature Reviews Neuroscience. 2008; 9 (2):85-96 - 42.
Pluess M, et al. 5-HTTLPR moderates effects of current life events on neuroticism: Differential susceptibility to environmental influences. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2010; 34 (6):1070-1074 - 43.
Karg K, et al. The serotonin transporter promoter variant (5-HTTLPR), stress, and depression meta-analysis revisited: Evidence of genetic moderation. Archives of General Psychiatry. 2011; 68 (5):444-454 - 44.
Suidan GL, et al. Lack of tryptophan hydroxylase-1 in mice results in gait abnormalities. PLoS One. 2013; 8 (3):e59032 - 45.
Rubenstein JL, Merzenich MM. Model of autism: Increased ratio of excitation/inhibition in key neural systems. Genes, Brain and Behavior. 2003; 2 (5):255-267 - 46.
Lewis DA, Hashimoto T, Volk DW. Cortical inhibitory neurons and schizophrenia. Nature Reviews Neuroscience. 2005; 6 (4):312-324 - 47.
Kawaguchi Y, Kondo S. Parvalbumin, somatostatin and cholecystokinin as chemical markers for specific GABAergic interneuron types in the rat frontal cortex. Journal of Neurocytology. 2002; 31 (3-5):277-287 - 48.
Sun QQ, Huguenard JR, Prince DA. Barrel cortex microcircuits: Thalamocortical feedforward inhibition in spiny stellate cells is mediated by a small number of fast-spiking interneurons. Journal of Neurosciences. 2006; 26 (4):1219-1230 - 49.
Inoue T, Imoto K. Feedforward inhibitory connections from multiple thalamic cells to multiple regular-spiking cells in layer 4 of the somatosensory cortex. Journal of Neurophysiology. 2006; 96 (4):1746-1754 - 50.
Karube F, Kubota Y, Kawaguchi Y. Axon branching and synaptic bouton phenotypes in GABAergic nonpyramidal cell subtypes. Journal of Neuroscience. 2004; 24 (12):2853-2865 - 51.
Ferezou I, et al. 5-HT3 receptors mediate serotonergic fast synaptic excitation of neocortical vasoactive intestinal peptide/cholecystokinin interneurons. Journal of Neuroscience. 2002; 22 (17):7389-7397 - 52.
Rudy B, et al., Three groups of interneurons account for nearly 100% of neocortical GABAergic neurons. Developmental Neurobiology. 2011; 71 (1):45-61 - 53.
Olah S, et al. Regulation of cortical microcircuits by unitary GABA-mediated volume transmission. Nature. 2009; 461 (7268):1278-1281 - 54.
Tricoire L, Vitalis T. Neuronal nitric oxide synthase expressing neurons: A journey from birth to neuronal circuits. Frontiers in Neural Circuits. 2012; 6 :82 - 55.
Perrenoud Q, et al. Characterization of Type I and Type II nNOS-Expressing interneurons in the barrel cortex of mouse. Frontiers in Neural Circuits. 2012; 6 :36 - 56.
Perrenoud Q, et al. Activation of cortical 5-HT(3) receptor-expressing interneurons induces NO mediated vasodilatations and NPY mediated vasoconstrictions. Frontiers in Neural Circuits. 2012; 6 :50 - 57.
Allman JM, et al. The von Economo neurons in the frontoinsular and anterior cingulate cortex. Annals of the New York Academy of Sciences. 2011; 1225 :59-71 - 58.
Dijkstra, A.A., et al., Von Economo Neurons and Fork Cells: A Neurochemical Signature Linked to Monoaminergic Function. Cereb Cortex, 2016;1-14. doi: 10.1093/cercor/bhw358. - 59.
Liu J, et al. Pathological changes of von economo neuron and fork neuron in neuropsychiatric diseases. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2016; 38 (1):113-117 - 60.
Collins CE, et al. Cortical cell and neuron density estimates in one chimpanzee hemisphere. Proceedings of the National Academy of Sciences of the United States. 2016; 113 (3):740-745 - 61.
Reemst K, et al. The indispensable roles of microglia and astrocytes during brain development. Frontiers in Human Neuroscience. 2016; 10 :566 - 62.
Ge WP, Jia JM. Local production of astrocytes in the cerebral cortex. Neuroscience. 2016; 323 :3-9 - 63.
Verney C, et al. Early microglial colonization of the human forebrain and possible involvement in periventricular white-matter injury of preterm infants. Journal of Anatomy. 2010; 217 (4):436-448 - 64.
Celada P, Puig MV, Artigas F. Serotonin modulation of cortical neurons and networks. Frontiers in Integrative Neuroscience. 2013; 7 :25 - 65.
Tork I. Anatomy of the serotonergic system. Annals of the New York Academy of Sciences. 1990; 600 :9-34. discussion 34-5 - 66.
Bystron I, Blakemore C, Rakic P. Development of the human cerebral cortex: Boulder Committee revisited. Nature Reviews Neuroscience. 2008; 9 (2):110-122 - 67.
Ginhoux F, et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science. 2010; 330 (6005):841-845 - 68.
Daneman R, et al. Pericytes are required for blood-brain barrier integrity during embryogenesis. Nature. 2010; 468 (7323):562-566 - 69.
Nie K, Molnar Z, Szele FG. Proliferation but not migration is associated with blood vessels during development of the rostral migratory stream. Developmental Neuroscience. 2010; 32 (3):163-172 - 70.
Rakic S, Zecevic N. Emerging complexity of layer I in human cerebral cortex. Cerebral Cortex. 2003; 13 (10):1072-1083 - 71.
Barber M, Pierani A. Tangential migration of glutamatergic neurons and cortical patterning during development: Lessons from Cajal-Retzius cells. Developmental Neuroscience. 2016; 76 (8):847-881 - 72.
Super H, et al. Disruption of neuronal migration and radial glia in the developing cerebral cortex following ablation of Cajal-Retzius cells. Cerebral Cortex. 2000; 10 (6):602-613 - 73.
Herz J, Chen Y. Reelin, lipoprotein receptors and synaptic plasticity. Nature Reviews Neuroscience. 2006; 7 (11):850-859 - 74.
Lakatosova S, Ostatnikova D. Reelin and its complex involvement in brain development and function. The International Journal of Biochemistry & Cell Biology. 2012; 44 (9):1501-1504 - 75.
Kriegstein AR, Noctor SC. Patterns of neuronal migration in the embryonic cortex. Trends in Neurosciences. 2004; 27 (7):392-329 - 76.
Corbin JG, et al. Regulation of neural progenitor cell development in the nervous system. Journal of Neurochemistry. 2008; 106 (6):2272-2287 - 77.
Hansen DV, et al. Neurogenic radial glia in the outer subventricular zone of human neocortex. Nature. 2010; 464 (7288):554-561 - 78.
LaMonica BE, et al. OSVZ progenitors in the human cortex: An updated perspective on neurodevelopmental disease. Current Opinion in Neurobiology. 2012; 22 (5):747-753 - 79.
Dehay C, Kennedy H. Cell-cycle control and cortical development. Nature Reviews Neuroscience. 2007; 8 (6):438-450 - 80.
Flames N, et al. Delineation of multiple subpallial progenitor domains by the combinatorial expression of transcriptional codes. Journal of Neuroscience. 2007; 27 (36):9682-9695 - 81.
Xu Q, et al. Origins of cortical interneuron subtypes. Journal of Neuroscience. 2004; 24 (11):2612-2622 - 82.
Butt SJ, et al. The temporal and spatial origins of cortical interneurons predict their physiological subtype. Neuron. 2005; 48 (4):591-604 - 83.
Miyoshi G, et al. Physiologically distinct temporal cohorts of cortical interneurons arise from telencephalic Olig2-expressing precursors. Journal of Neuroscience. 2007; 27 (29):7786-7798 - 84.
Wonders CP, et al. A spatial bias for the origins of interneuron subgroups within the medial ganglionic eminence. Developmental Biology. 2008; 314 (1):127-136 - 85.
Kessaris N, et al. Genetic programs controlling cortical interneuron fate. Current Opinion in Neurobiology. 2014; 26 :79-87 - 86.
Fogarty M, et al. Spatial genetic patterning of the embryonic neuroepithelium generates GABAergic interneuron diversity in the adult cortex. Journal of Neuroscience. 2007; 27 (41):10935-10946 - 87.
Touzot A, et al. Molecular control of two novel migratory paths for CGE-derived interneurons in the developing mouse brain. Development. 2016; 143 (10):1753-1765 - 88.
Vucurovic K, et al. Serotonin 3A receptor subtype as an early and protracted marker of cortical interneuron subpopulations. Cerebral Cortex. 2010; 20 (10):2333-2347 - 89.
Miyoshi G, et al. Prox1 regulates the Subtype-Specific development of caudal ganglionic Eminence-Derived GABAergic cortical interneurons. Journal of Neuroscience. 2015; 35 (37):12869-12889 - 90.
Inta D, et al. Neurogenesis and widespread forebrain migration of distinct GABAergic neurons from the postnatal subventricular zone. Proceedings of the National Academy of Sciences of the United States. 2008; 105 (52):20994-20999 - 91.
Riccio O, et al. New pool of cortical interneuron precursors in the early postnatal dorsal white matter. Cerebral Cortex. 2012; 22 (1):86-98 - 92.
Frazer S, Otomo K, Dayer A. Early-life serotonin dysregulation affects the migration and positioning of cortical interneuron subtypes. Translational Psychiatry. 2015; 5 :e644 - 93.
Ma T, et al. Subcortical origins of human and monkey neocortical interneurons. Nature Neuroscience. 2013; 16 (11):1588-1597 - 94.
Verney C. Phenotypic expression of monoamines and GABA in the early development of human telencephalon, transient or not transient. Journal of Chemical Neuroanatomy. 2003; 26 (4):283-292 - 95.
Petanjek Z, Berger B, Esclapez M. Origins of cortical GABAergic neurons in the cynomolgus monkey. Cerebral Cortex. 2009; 19 (2):249-262 - 96.
Yu X, Zecevic N. Dorsal radial glial cells have the potential to generate cortical interneurons in human but not in mouse brain. Journal of Neuroscience. 2011; 31 (7):2413-2420 - 97.
Paredes MF, et al. Extensive migration of young neurons into the infant human frontal lobe. Science. 2016; 354 (6308):aaf7073 - 98.
Meyer G. Building a human cortex: The evolutionary differentiation of Cajal-Retzius cells and the cortical hem. Journal of Anatomy. 2010; 217 (4):334-343 - 99.
Verney C, Derer P. Cajal-Retzius neurons in human cerebral cortex at midgestation show immunoreactivity for neurofilament and calcium-binding proteins. Journal of Comparative Neurology. 1995; 359 (1):144-153 - 100.
Molliver ME, Kostovic I, van der Loos H. The development of synapses in cerebral cortex of the human fetus. Brain Research. 1973; 50 (2):403-407 - 101.
Duque A, et al. Secondary expansion of the transient subplate zone in the developing cerebrum of human and nonhuman primates. Proceedings of the National Academy of Sciences of the United States. 2016; 113 (35):9892-9897 - 102.
Zecevic N, Verney C. Development of the catecholamine neurons in human embryos and fetuses, with special emphasis on the innervation of the cerebral cortex. Journal of Comparative Neurology. 1995; 351 (4):509-535 - 103.
Kostovic I, Rakic P. Developmental history of the transient subplate zone in the visual and somatosensory cortex of the macaque monkey and human brain. Journal of Comparative Neurology. 1990; 297 (3):441-470 - 104.
Kostovic I, Rakic P. Cytology and time of origin of interstitial neurons in the white matter in infant and adult human and monkey telencephalon. Journal of Neurocytology. 1980; 9 (2):219-242 - 105.
Defelipe J, et al. Cortical white matter: Beyond the pale remarks, main conclusions and discussion. Frontiers in Neuroanatomy. 2010; 4 :4 - 106.
Xu G, et al. Late development of the GABAergic system in the human cerebral cortex and white matter. Journal of Neuropathology & Experimental Neurology. 2011; 70 (10):841-858 - 107.
Czeh M, Gressens P, Kaindl AM. The yin and yang of microglia. Developmental Neuroscience. 2011; 33 (3-4):199-209 - 108.
Rezaie P, et al. Microglia in the cerebral wall of the human telencephalon at second trimester. Cerebral Cortex. 2005; 15 (7):938-949 - 109.
Monier A, et al. Distribution and differentiation of microglia in the human encephalon during the first two trimesters of gestation. Journal of Comparative Neurology. 2006; 499 (4):565-582 - 110.
Monier A, et al. Entry and distribution of microglial cells in human embryonic and fetal cerebral cortex. Journal of Neuropathology & Experimental Neurology. 2007; 66 (5):372-382 - 111.
Verney C, et al. Microglial reaction in axonal crossroads is a hallmark of noncystic periventricular white matter injury in very preterm infants. Journal of Neuropathology & Experimental Neurology. 2012; 71 (3):251-264 - 112.
Baud O, et al. Gestational hypoxia induces white matter damage in neonatal rats: A new model of periventricular leukomalacia. Brain Pathology. 2004; 14 (1):1-10 - 113.
Olivier P, et al. Prenatal ischemia and white matter damage in rats. Journal of Neuropathology & Experimental Neurology. 2005; 64 (11):998-1006 - 114.
Olivier P, et al. Moderate growth restriction: Deleterious and protective effects on white matter damage. Neurobiology of Disease. 2007; 26 (1):253-263 - 115.
Oberheim NA, et al. Astrocytic complexity distinguishes the human brain. Trends in Neurosciences. 2006; 29 (10):547-553 - 116.
Howard B, Chen Y, Zecevic N. Cortical progenitor cells in the developing human telencephalon. Glia. 2006; 53 (1):57-66 - 117.
Baud O, et al. Perinatal and early postnatal changes in the expression of monocarboxylate transporters MCT1 and MCT2 in the rat forebrain. Journal of Comparative Neurology. 2003; 465 (3):445-454 - 118.
Belanger M, Allaman I, Magistretti PJ. Brain energy metabolism: Focus on astrocyte-neuron metabolic cooperation. Cell Metabolism. 2011; 14 (6):724-738 - 119.
Fayol L, et al. Immunocytochemical expression of monocarboxylate transporters in the human visual cortex at midgestation. Brain Research. Developmental Brain Research. 2004; 148 (1):69-76 - 120.
Ribatti D, et al. Development of the blood-brain barrier: A historical point of view. The Anatomical Record. 2006; 289 (1):3-8 - 121.
Walther DJ, et al. Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science. 2003; 299 (5603):76 - 122.
Patel PD, Pontrello C, Burke S. Robust and tissue-specific expression of TPH2 versus TPH1 in rat raphe and pineal gland. Biological Psychiatry. 2004; 55 (4):428-433 - 123.
Cote F, et al. Disruption of the nonneuronal tph1 gene demonstrates the importance of peripheral serotonin in cardiac function. Proceedings of the National Academy of Sciences of the United States. 2003; 100 (23):13525-13530 - 124.
Shih JC, Grimsby J, Chen K. The expression of human MAO-A and B genes. Journal of Neural Transmission Supplement. 1990; 32 :41-47 - 125.
Grimsby J, et al. Tissue distribution of human monoamine oxidase A and B mRNA. Journal of Neurochemistry. 1990; 55 (4):1166-1169 - 126.
Vitalis T, et al. Developmental expression of monoamine oxidases A and B in the central and peripheral nervous systems of the mouse. Journal of Comparative Neurology. 2002; 442 (4):331-347 - 127.
Wu HH, Choi S, Levitt P. Differential patterning of genes involved in serotonin metabolism and transport in extra-embryonic tissues of the mouse. Placenta. 2016; 42 :74-83 - 128.
Steinbusch HW. Distribution of serotonin-immunoreactivity in the central nervous system of the rat-cell bodies and terminals. Neuroscience. 1981; 6 (4):557-618 - 129.
Lidov HG, Molliver ME. An immunohistochemical study of serotonin neuron development in the rat: Ascending pathways and terminal fields. Brain Research Bulletin. 1982; 8 (4):389-430 - 130.
Muzerelle A, et al. Conditional anterograde tracing reveals distinct targeting of individual serotonin cell groups (B5-B9) to the forebrain and brainstem. Brain Structure and Function. 2016; 221 (1):535-561 - 131.
Wallace JA, Lauder JM. Development of the serotonergic system in the rat embryo: An immunocytochemical study. Brain Research Bulletin. 1983; 10 (4):459-479 - 132.
Aitken AR, Tork I. Early development of serotonin-containing neurons and pathways as seen in wholemount preparations of the fetal rat brain. Journal of Comparative Neurology. 1988; 274 (1):32-47 - 133.
Radnikow G, Feldmeyer D, Lubke J. Axonal projection, input and output synapses, and synaptic physiology of Cajal-Retzius cells in the developing rat neocortex. Journal of Neurosciences. 2002; 22 (16):6908-6919 - 134.
Janusonis S, Gluncic V, Rakic P. Early serotonergic projections to Cajal-Retzius cells: Relevance for cortical development. Journal of Neurosciences. 2004; 24 (7):1652-1659 - 135.
Hornung JP, Celio MR. The selective innervation by serotoninergic axons of calbindin-containing interneurons in the neocortex and hippocampus of the marmoset. Journal of Comparative Neurology. 1992; 320 (4):457-467 - 136.
Azmitia EC, Gannon PJ. The primate serotonergic system: A review of human and animal studies and a report on Macaca fascicularis. Advances in Neurology. 1986; 43 :407-468 - 137.
Berger B, et al. Regional and laminar distribution of the dopamine and serotonin innervation in the macaque cerebral cortex: A radioautographic study. Journal of Comparative Neurology. 1988; 273 (1):99-119 - 138.
Hornung JP. The human raphe nuclei and the serotonergic system. Journal of Chemical Neuroanatomy. 2003; 26 (4):331-343 - 139.
Levitt P, Rakic P. The time of genesis, embryonic origin and differentiation of the brain stem monoamine neurons in the rhesus monkey. Brain Research. 1982; 256 (1):35-57 - 140.
Berger B, Alvarez C, Goldman-Rakic PS. Neurochemical development of the hippocampal region in the fetal rhesus monkey. I. Early appearance of peptides, calcium-binding proteins, DARPP-32, and monoamine innervation in the entorhinal cortex during the first half of gestation (E47 to E90). Hippocampus. 1993; 3 (3):279-305 - 141.
Verney C, et al. Immunocytochemical evidence of well-developed dopaminergic and noradrenergic innervations in the frontal cerebral cortex of human fetuses at midgestation. Journal of Comparative Neurology. 1993; 336 (3):331-344 - 142.
Verney C, Lebrand C, Gaspar P. Changing distribution of monoaminergic markers in the developing human cerebral cortex with special emphasis on the serotonin transporter. The Anatomical Record. 2002; 267 (2):87-93 - 143.
Lebrand C, et al. Transitory uptake of serotonin in the developing sensory pathways of the common marmoset. Journal of Comparative Neurology. 2006; 499 (4):677-689 - 144.
Lauder JM, Krebs H. Serotonin as a differentiation signal in early neurogenesis. Developmental Neuroscience. 1978; 1 (1):15-30 - 145.
Shuey DL, Sadler TW, Lauder JM. Serotonin as a regulator of craniofacial morphogenesis: Site specific malformations following exposure to serotonin uptake inhibitors. Teratology. 1992; 46 (4):367-378 - 146.
Yavarone MS, et al. Serotonin uptake in the ectoplacental cone and placenta of the mouse. Placenta. 1993; 14 (2):149-161 - 147.
Moiseiwitsch JR, Lauder JM. Serotonin regulates mouse cranial neural crest migration. Proceedings of the National Academy of Sciences of the United States. 1995; 92 (16):7182-7186 - 148.
Whitaker-Azmitia PM, et al. Serotonin as a developmental signal. Behavioural Brain Research. 1996; 73 (1-2):19-29 - 149.
Buznikov GA, Lambert HW, Lauder JM. Serotonin and serotonin-like substances as regulators of early embryogenesis and morphogenesis. Cell Tissue Research. 2001; 305 (2):177-186 - 150.
Bonnin A, et al. A transient placental source of serotonin for the fetal forebrain. Nature. 2011; 472 (7343):347-350 - 151.
Smidt MP, et al. A second independent pathway for development of mesencephalic dopaminergic neurons requires Lmx1b. Nature Neuroscience. 2000; 3 (4):337-341 - 152.
Hendricks T, et al. The ETS domain factor Pet-1 is an early and precise marker of central serotonin neurons and interacts with a conserved element in serotonergic genes. Journal of Neuroscience. 1999; 19 (23):10348-10356 - 153.
Alenina N, et al. Growth retardation and altered autonomic control in mice lacking brain serotonin. Proceedings of the National Academy of Sciences of the United States. 2009; 106 (25):10332-10337 - 154.
Migliarini S, et al. Lack of brain serotonin affects postnatal development and serotonergic neuronal circuitry formation. Molecular Psychiatry. 2012; 18 (10):1106-1118 - 155.
Jankovic BD. Neuroimmunomodulation: Facts and dilemmas. Immunology Letters. 1989; 21 (2):101-118 - 156.
Zhuang X, Silverman AJ, Silver R. Brain mast cell degranulation regulates blood-brain barrier. Journal of Neurobiology. 1996; 31 (4):393-403 - 157.
Cases O, et al. Plasma membrane transporters of serotonin, dopamine, and norepinephrine mediate serotonin accumulation in atypical locations in the developing brain of monoamine oxidase A knock-outs. Journal of Neuroscience. 1998; 18 (17):6914-6927 - 158.
Lebrand C, et al. Transient developmental expression of monoamine transporters in the rodent forebrain. Journal of Comparative Neurology. 1998; 401 (4):506-524 - 159.
Vitalis T, et al. Interactions between TrkB signaling and serotonin excess in the developing murine somatosensory cortex: A role in tangential and radial organization of thalamocortical axons. Journal of Neuroscience. 2002; 22 (12):4987-5000 - 160.
Dehay C, et al. Cell-cycle kinetics of neocortical precursors are influenced by embryonic thalamic axons. Journal of Neuroscience. 2001; 21 (1):201-214 - 161.
Edgar JM, Price DJ. Radial migration in the cerebral cortex is enhanced by signals from thalamus. European Journal of Neuroscience. 2001; 13 (9):1745-1754 - 162.
Hoyer D, et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacological Reviews. 1994; 46 (2):157-203 - 163.
Hoyer D, Hannon JP, Martin GR. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacology Biochemistry and Behavior. 2002; 71 (4):533-554 - 164.
Raymond JR, et al. Multiplicity of mechanisms of serotonin receptor signal transduction. Pharmacology & Therapeutics. 2001; 92 (2-3):179-212 - 165.
Millan MJ, et al. Signaling at G-protein-coupled serotonin receptors: Recent advances and future research directions. Trends in Pharmacological Sciences. 2008; 29 (9):454-464 - 166.
Chameau P, van Hooft JA. Serotonin 5-HT(3) receptors in the central nervous system. Cell Tissue Research. 2006; 326 (2):573-581 - 167.
Tecott LH, Maricq AV, Julius D. Nervous system distribution of the serotonin 5-HT3 receptor mRNA. Proceedings of the National Academy of Sciences of the United States. 1993; 90 (4):1430-1434 - 168.
Morales M, Bloom FE. The 5-HT3 receptor is present in different subpopulations of GABAergic neurons in the rat telencephalon. Journal of Neuroscience. 1997; 17 (9):3157-3167 - 169.
Davies PA, et al. The 5-HT3B subunit is a major determinant of serotonin-receptor function. Nature. 1999; 397 (6717):359-363 - 170.
Krabbe G, et al. Activation of serotonin receptors promotes microglial injury-induced motility but attenuates phagocytic activity. Brain, Behavior, and Immunity. 2012; 26 (3):419-428 - 171.
Kolodziejczak M, et al. Serotonin modulates developmental microglia via 5-HT2B receptors: Potential implication during synaptic refinement of retinogeniculate projections. ACS Chemical Neuroscience. 2015; 6 (7):1219-1230 - 172.
Johnson DS, Heinemann SF. Embryonic expression of the 5-HT3 receptor subunit, 5-HT3R-A, in the rat: An in situ hybridization study. Molecular and Cellular Neuroscience. 1995; 6 (2):122-138 - 173.
Chameau P, et al. The N-terminal region of reelin regulates postnatal dendritic maturation of cortical pyramidal neurons. Proceedings of the National Academy of Sciences of the United States. 2009; 106 (17):7227-7232 - 174.
Riccio O, et al. Excess of serotonin affects neocortical pyramidal neuron migration. Translational Psychiatry. 2011; 1 :e47 - 175.
Dayer AG, et al. 5-HT6 receptor: A new player controlling the development of neural circuits. ACS Chemical Neuroscience. 2015; 6 (7):951-960 - 176.
Lee S, et al. The largest group of superficial neocortical GABAergic interneurons expresses ionotropic serotonin receptors. Journal of Neuroscience. 2010; 30 (50):16796-16808 - 177.
Narboux-Neme N, et al. Postnatal growth defects in mice with constitutive depletion of central serotonin. ACS Chemical Neuroscience. 2013; 4 (1):171-181 - 178.
Dooley AE, Pappas IS, Parnavelas JG. Serotonin promotes the survival of cortical glutamatergic neurons in vitro. Experimental Neurology. 1997; 148 (1):205-214 - 179.
Bielenberg GW, Burkhardt M. 5-hydroxytryptamine1A agonists. A new therapeutic principle for stroke treatment. Stroke. 1990; 21 (12 Suppl):IV161-IV163 - 180.
Ahlemeyer B, et al. S-100beta protects cultured neurons against glutamate- and staurosporine-induced damage and is involved in the antiapoptotic action of the 5 HT(1A)-receptor agonist, Bay x 3702. Brain Research. 2000; 858 (1):121-128 - 181.
Stankovski L, et al. Developmental cell death is enhanced in the cerebral cortex of mice lacking the brain vesicular monoamine transporter. Journal of Neuroscience. 2007; 27 (6):1315-1324 - 182.
Cheng A, et al. Monoamine oxidases regulate telencephalic neural progenitors in late embryonic and early postnatal development. Journal of Neuroscience. 2010; 30 (32):10752-10762 - 183.
Roerig B, Feller MB. Neurotransmitters and gap junctions in developing neural circuits. Brain Research. Brain Research Reviews. 2000; 32 (1):86-114 - 184.
Bittman K, et al. Cell coupling and uncoupling in the ventricular zone of developing neocortex. Journal of Neuroscience. 1997; 17 (18):7037-7044 - 185.
Khan N, Deschaux P. Role of serotonin in fish immunomodulation. The Journal of Experimental Biology. 1997; 200 (Pt 13):1833-1838 - 186.
Boehme SA, et al. Cutting edge: Serotonin is a chemotactic factor for eosinophils and functions additively with eotaxin. Journal of Immunology. 2004; 173 (6):3599-3603 - 187.
Vitalis T, et al. Embryonic depletion of serotonin affects cortical development. European Journal of Neuroscience. 2007; 26 (2):331-344 - 188.
Waider J, et al. GABA concentration and GABAergic neuron populations in limbic areas are differentially altered by brain serotonin deficiency in Tph2 knockout mice. Histochemistry and Cell Biology. 2013; 139 (2):267-281 - 189.
Murthy S, et al. Serotonin receptor 3A controls interneuron migration into the neocortex. Nature Communications. 2014; 5 :5524 - 190.
Jakab R.L, Goldman-Rakic PS. Segregation of serotonin 5-HT2A and 5-HT3 receptors in inhibitory circuits of the primate cerebral cortex. Journal of Comparative Neurology. 2000; 417 (3):337-348 - 191.
Riccio O, et al. Excess of serotonin affects embryonic interneuron migration through activation of the serotonin receptor 6. Journal of Molecular Psychiatry. 2009; 14 (3):280-290 - 192.
Lauder JM. Neurotransmitters as growth regulatory signals: Role of receptors and second messengers. Trends Neurosciences. 1993; 16 (6):233-240 - 193.
Bar-Peled O, et al. Fetal human brain exhibits a prenatal peak in the density of serotonin 5-HT1A receptors. Neuroscience Letters. 1991; 127 (2):173-176 - 194.
Homberg JR, Schubert D, Gaspar P. New perspectives on the neurodevelopmental effects of SSRIs. Trends in Pharmacological Sciences. 2009; 31 (2):60-65 - 195.
Smit-Rigter LA, et al. Prenatal fluoxetine exposure induces life-long serotonin 5-HT(3) receptor-dependent cortical abnormalities and anxiety-like behaviour. Neuropharmacology. 2012; 62 (2):865-870 - 196.
Smit-Rigter LA, Wadman WJ, van Hooft JA. Alterations in apical dendrite bundling in the somatosensory cortex of 5-HT(3A) receptor knockout mice. Frontiers in Neuroanatomy. 2011; 5 :64 - 197.
Gonzalez-Burgos I, et al. Tryptophan restriction causes long-term plastic changes in corticofrontal pyramidal neurons. International Journal of Developmental Neuroscience. 1996; 14 (5):673-679 - 198.
Feria-Velasco A, del Angel AR, Gonzalez-Burgos I. Modification of dendritic development. Progress in Brain Research. 2002; 136 :135-143 - 199.
Gross C, et al. Serotonin1A receptor acts during development to establish normal anxiety-like behaviour in the adult. Nature. 2002; 416 (6879):396-400 - 200.
Vitalis T, Ansorge MS, Dayer AG. Serotonin homeostasis and serotonin receptors as actors of cortical construction: Special attention to the 5-HT3A and 5-HT6 receptor subtypes. Front Cell Neuroscience. 2013; 7 :93 - 201.
Vitalis T, et al. Effects of monoamine oxidase A inhibition on barrel formation in the mouse somatosensory cortex: Determination of a sensitive developmental period. Journal of Comparative Neurology. 1998; 393 (2):169-184 - 202.
Salichon N, et al. Excessive activation of serotonin (5-HT) 1B receptors disrupts the formation of sensory maps in monoamine oxidase a and 5-ht transporter knock-out mice. Journal of Neuroscience. 2001; 21 (3):884-896 - 203.
Persico AM, et al. Barrel pattern formation requires serotonin uptake by thalamocortical afferents, and not vesicular monoamine release. Journal of Neuroscience. 2001; 21 (17):6862-6873 - 204.
Rebsam A, Seif I, Gaspar P. Refinement of thalamocortical arbors and emergence of barrel domains in the primary somatosensory cortex: A study of normal and monoamine oxidase a knock-out mice. Journal of Neuroscience. 2002; 22 (19):8541-8552 - 205.
van Kleef ES, Gaspar P, Bonnin A. Insights into the complex influence of 5-HT signaling on thalamocortical axonal system development. European Journal of Neuroscience. 2012; 35 (10):1563-1572 - 206.
Upton AL, et al. Excess of serotonin (5-HT) alters the segregation of ispilateral and contralateral retinal projections in monoamine oxidase A knock-out mice: Possible role of 5-HT uptake in retinal ganglion cells during development. Journal of Neuroscience. 1999; 19 (16):7007-7024 - 207.
Bennett-Clarke CA, et al. Effect of serotonin depletion on vibrissa-related patterns of thalamic afferents in the rat's somatosensory cortex. Journal of Neuroscience. 1994; 14 (12):7594-7607 - 208.
Osterheld-Haas MC, Van der Loos H, Hornung JP. Monoaminergic afferents to cortex modulate structural plasticity in the barrelfield of the mouse. Brain Research Developmental Brain Research. 1994; 77 (2):189-202 - 209.
Bonnin A, et al. Serotonin modulates the response of embryonic thalamocortical axons to netrin-1. Nature Neuroscience. 2007; 10 (5):588-597 - 210.
Azmitia EC, et al. 5-HT1A agonist and dexamethasone reversal of para-chloroamphetamine induced loss of MAP-2 and synaptophysin immunoreactivity in adult rat brain. Brain Research. 1995; 677 (2):181-192 - 211.
Wilson CC, Faber KM, Haring JH. Serotonin regulates synaptic connections in the dentate molecular layer of adult rats via 5-HT1a receptors: Evidence for a glial mechanism. Brain Research. 1998; 782 (1-2):235-239 - 212.
Pont-Lezica L, et al. Physiological roles of microglia during development. Journal of Neurochemistry. 2011; 119 (5):901-908 - 213.
Wake H, et al. Resting microglia directly monitor the functional state of synapses in vivo and determine the fate of ischemic terminals. Journal of Neuroscience. 2009; 29 (13):3974-3980 - 214.
Paolicelli RC, et al. Synaptic pruning by microglia is necessary for normal brain development. Science. 2011; 333 (6048):1456-1458 - 215.
Paolicelli RC, Gross CT. Microglia in development: Linking brain wiring to brain environment. Neuron Glia Biology. 2011; 7 (1):77-83 - 216.
Hoshiko M, et al. Deficiency of the microglial receptor CX3CR1 impairs postnatal functional development of thalamocortical synapses in the barrel cortex. Journal of Neuroscience. 2012; 32 (43):15106-15111 - 217.
Brunner HG, et al. Abnormal behavior associated with a point mutation in the structural gene for monoamine oxidase A. Science. 1993; 262 (5133):578-580 - 218.
Naoi M, Riederer P, Maruyama W. Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: Genetic and environmental factors involved in type A MAO expression. Journal of Neural Transmission (Vienna). 2016; 123 (2):91-106 - 219.
Glover ME, Clinton SM. Of rodents and humans: A comparative review of the neurobehavioral effects of early life SSRI exposure in preclinical and clinical research. International Journal of Developmental Neuroscience. 2016; 51 :50-72 - 220.
Rurak D, et al. Third trimester fetal heart rate and Doppler middle cerebral artery blood flow velocity characteristics during prenatal selective serotonin reuptake inhibitor exposure. Pediatric Research. 2011; 70 (1):96-101 - 221.
El Marroun H, et al. Maternal use of selective serotonin reuptake inhibitors, fetal growth, and risk of adverse birth outcomes. Archives of General Psychiatry. 2012; 69 (7):706-714 - 222.
Casper RC, et al. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. Journal of Pediatrics. 2003; 142 (4):402-408 - 223.
Oberlander TF, et al. Pain reactivity in 2-month-old infants after prenatal and postnatal serotonin reuptake inhibitor medication exposure. Pediatrics. 2005; 115 (2):411-425 - 224.
Casper RC, et al. Length of prenatal exposure to selective serotonin reuptake inhibitor (SSRI) antidepressants: Effects on neonatal adaptation and psychomotor development. Psychopharmacology (Berl). 2011; 217 (2):211-219 - 225.
Croen LA, et al. Antidepressant use during pregnancy and childhood autism spectrum disorders. Archives of General Psychiatry. 2011; 68 (11):1104-1112 - 226.
Oberlander TF, et al. Prenatal effects of selective serotonin reuptake inhibitor antidepressants, serotonin transporter promoter genotype (SLC6A4), and maternal mood on child behavior at 3 years of age. Archives of Pediatrics and Adolescent Medicine. 2010; 164 (5):444-451 - 227.
Yubero-Lahoz S, et al. Platelet SERT as a peripheral biomarker of serotonergic neurotransmission in the central nervous system. Current Medicinal Chemistry. 2013; 20 (11):1382-1396 - 228.
Janusonis S. Serotonin dynamics in and around the central nervous system: Is autism solvable without fundamental insights? International Journal of Developmental Neuroscience. 2014; 39 :9-15 - 229.
Levitt P, Campbell DB. The genetic and neurobiologic compass points toward common signaling dysfunctions in autism spectrum disorders. Journal of Clinical Investigation. 2009; 119 (4):747-754 - 230.
Page DT, et al. Haploinsufficiency for Pten and Serotonin transporter cooperatively influences brain size and social behavior. Proceedings of the National Academy of Sciences of the United States. 2009; 106 (6):1989-1994 - 231.
Giudici V, et al. Serotonin reuptake inhibitors in pregnancy: Can genes help us in predicting neonatal adverse outcome? BioMed Research International. 2012; 2014 :276918 - 232.
Hammer C, et al. Replication of functional serotonin receptor type 3A and B variants in bipolar affective disorder: A European multicenter study. Translational Psychiatry. 2012; 2 :e103 - 233.
Perroud N, et al. Methylation of serotonin receptor 3A in ADHD, borderline personality, and bipolar disorders: Link with severity of the disorders and childood maltreatment. Depress Anxiety. 2016; 33 (1):45-55 - 234.
Gatt JM, et al. Early life stress combined with serotonin 3A receptor and brain-derived neurotrophic factor valine 66 to methionine genotypes impacts emotional brain and arousal correlates of risk for depression. Biological Psychiatry. 2010; 68 (9):818-824 - 235.
Gatt JM, et al. Impact of the HTR3A gene with early life trauma on emotional brain networks and depressed mood. Depress Anxiety. 2010; 27 (8):752-759 - 236.
Pierre WC, et al. Neonatal microglia: The cornerstone of brain fate. Brain, Behavior, and Immunity. 2017; 59 :333-345 - 237.
Hagberg H, et al. The role of inflammation in perinatal brain injury. Nature Reviews Neurology. 2015; 11 (4):192-208 - 238.
Fleiss B, et al. Inflammation-induced sensitization of the brain in term infants. Developmental Medicine & Child Neurology. 2015; 57 (Suppl 3):17-28 - 239.
Fan LW, et al. Dopaminergic neuronal injury in the adult rat brain following neonatal exposure to lipopolysaccharide and the silent neurotoxicity. Brain, Behavior, and Immunity. 2011; 25 (2):286-297 - 240.
Williamson LL, et al. Microglia and memory: Modulation by early-life infection. Journal of Neuroscience. 2011; 31 (43):15511-15521 - 241.
Hagberg H, Gressens P, Mallard C. Inflammation during fetal and neonatal life: Implications for neurologic and neuropsychiatric disease in children and adults. Annals of Neurology. 2012; 71 (4):444-457 - 242.
Wixey JA, et al. Efficacy of post-insult minocycline administration to alter long-term hypoxia-ischemia-induced damage to the serotonergic system in the immature rat brain. Neuroscience. 2011;182:184-192 - 243.
Reinebrant HE, Wixey JA, Buller KM. Neonatal hypoxia-ischaemia disrupts descending neural inputs to dorsal raphe nuclei. Neuroscience. 2013;248:427-435